Clearance of Inflammatory Cytokines During Renal Replacement Therapy Using the EMIC®2 Filter

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

12 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-01

Study Completion Date

2018-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be conducted in patients with sepsis and acute kidney injury needing renal replacement therapy.

The aim is to investigate whether continuous renal replacement therapy with the EMIC®2 filter leads to removal of pro-inflammatory middle molecular weight cytokines from the blood.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Elimination of Antibiotics During Renal Replacement Therapy and Cytosorb Adsorptive Therapy

NCT02611271

Critical Illness Sepsis Acute Kidney Injury

UNKNOWN

Evaluation of Catheter Placement for Renal Replacement Therapy in Patients With Acute Kidney Injury

NCT02200120

Acute Kidney Injury

COMPLETED

Promoting Kidney Recovery After Acute Kidney Injury Receiving Dialysis

NCT04948476

Acute Kidney Injury

COMPLETED NA

Filter Lifespan in Continuous Renal Replacement Therapy

NCT05450185

Critically Ill Continuous Renal Replacement Therapy Infections

RECRUITING

Continuous Renal Replacement Therapy With Oxiris in Acute Kidney Injury and Sepsis

NCT06253377

Acute Kidney Injury Sepsis

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In patients with acute kidney injury (AKI) and sepsis requiring renal replacement therapy, the investigators aim to determine whether continuous veno-venous haemodialysis with an EMiC®2 filter leads to clearance of the following mediators Interleukin (IL) -1 alpha, IL-1 beta, IL-2, IL- 4, IL-6, IL-8, IL-10, Tissue necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), Interferon gamma, Monocyte chemotactic protein-1 and epidermal growth factor.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Renal Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adult patients (≥18 years) in the Critical Care Unit with AKI and sepsis
* clinical decision that citrate based continuous veno-venous haemodialysis (CVVHD) is necessary

Exclusion Criteria

* lack of consent
* pre-existing dialysis dependent renal failure
* life expectancy \<24 hours
* patients with haemoglobin \<7g/dL (unless transfused for clinical reasons)
* need for extracorporeal membrane oxygenation (ECMO)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No